84 related articles for article (PubMed ID: 16361126)
41. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
42. Anatomic and functional imaging in the management of lymphoma.
Al-Nahhas A; Win Z; Al-Sayed Y; Khan S; Singh A; Rubello D; Gishen P
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):251-9. PubMed ID: 17538524
[TBL] [Abstract][Full Text] [Related]
43. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
Ribrag V; Vanel D; Leboulleux S; Lumbroso J; Couanet D; Bonniaud G; Aupérin A; Masson F; Bosq J; Edeline V; Fermé C; Pigneur F; Schlumberger M
Eur J Radiol; 2008 May; 66(2):325-31. PubMed ID: 17651934
[TBL] [Abstract][Full Text] [Related]
44. Whole-body MRI for the staging and follow-up of patients with metastasis.
Schmidt GP; Reiser MF; Baur-Melnyk A
Eur J Radiol; 2009 Jun; 70(3):393-400. PubMed ID: 19457631
[TBL] [Abstract][Full Text] [Related]
45. Use of imaging in the management of lymphoma.
Golding SJ
Br J Hosp Med; 1989 Feb; 41(2):152-4, 156-7. PubMed ID: 2653532
[TBL] [Abstract][Full Text] [Related]
46. Follicular lymphoma international prognostic index.
Solal-Céligny P; Roy P; Colombat P; White J; Armitage JO; Arranz-Saez R; Au WY; Bellei M; Brice P; Caballero D; Coiffier B; Conde-Garcia E; Doyen C; Federico M; Fisher RI; Garcia-Conde JF; Guglielmi C; Hagenbeek A; Haïoun C; LeBlanc M; Lister AT; Lopez-Guillermo A; McLaughlin P; Milpied N; Morel P; Mounier N; Proctor SJ; Rohatiner A; Smith P; Soubeyran P; Tilly H; Vitolo U; Zinzani PL; Zucca E; Montserrat E
Blood; 2004 Sep; 104(5):1258-65. PubMed ID: 15126323
[TBL] [Abstract][Full Text] [Related]
47. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
48. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson BD; Horning SJ; Coiffier B; Shipp MA; Fisher RI; Connors JM; Lister TA; Vose J; Grillo-López A; Hagenbeek A; Cabanillas F; Klippensten D; Hiddemann W; Castellino R; Harris NL; Armitage JO; Carter W; Hoppe R; Canellos GP
J Clin Oncol; 1999 Apr; 17(4):1244. PubMed ID: 10561185
[TBL] [Abstract][Full Text] [Related]
49. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
Hasenclever D; Diehl V
N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
[TBL] [Abstract][Full Text] [Related]
50. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
[TBL] [Abstract][Full Text] [Related]
51. A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med; 1993 Sep; 329(14):987-94. PubMed ID: 8141877
[TBL] [Abstract][Full Text] [Related]
52. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
Noordijk EM; Carde P; Mandard AM; Mellink WA; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Dupouy N
Ann Oncol; 1994; 5 Suppl 2():107-12. PubMed ID: 7515643
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy.
Lee CK; Bloomfield CD; Goldman AI; Levitt SH
Cancer; 1980 Dec; 46(11):2403-9. PubMed ID: 7438015
[TBL] [Abstract][Full Text] [Related]
54. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
Lister TA; Crowther D; Sutcliffe SB; Glatstein E; Canellos GP; Young RC; Rosenberg SA; Coltman CA; Tubiana M
J Clin Oncol; 1989 Nov; 7(11):1630-6. PubMed ID: 2809679
[TBL] [Abstract][Full Text] [Related]
55. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.
Tubiana M; Henry-Amar M; Carde P; Burgers JM; Hayat M; Van der Schueren E; Noordijk EM; Tanguy A; Meerwaldt JH; Thomas J
Blood; 1989 Jan; 73(1):47-56. PubMed ID: 2462943
[TBL] [Abstract][Full Text] [Related]
56. Role of imaging to choose treatment.
Fermé C; Vanel D; Ribrag V; Girinski T
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S113-9. PubMed ID: 16361126
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
